lymphoma

[News Medical Life Sciences] An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.

[PLoS One] Scientists revealed a lymphoid TBX-code and used it to identify an aberrant network around deregulated T-box gene TBX3 in Hodgkin lymphoma which promoted hallmark aberrations of this disease.

[Blood Advances] Researchers reported results of a phase Ib dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory diffuse large B cell lymphoma.

[Biochemical Pharmacology] Luxeptinib inhibited the release of three cytokines from THP-1 monocytes and macrophages at concentrations of 0.1 µM and above.

[eLife] The authors characterized cell free DNA released from specific immune cell types in healthy individuals, cross sectionally and longitudinally.

[Nature Reviews Disease Primers] VEGF is a potent angiogenic factor that may have a role in the pathogenesis of the Kaposi sarcoma herpesvirus (KSHV)-negative idiopathic form of multicentric Castelman disease (MCD) and KSHV-MCD, as endothelial cell and blood vessel proliferation is an important component of MCD.